EMA committee supports Simbrinza safety, efficacy for glaucoma

Alcon announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency supports the safety and efficacy of brinzolamide eye drops suspension for adult patients with open-angle glaucoma or ocular hypertension, according to a press release.Brinzolamide 10 mg/mL and brimonidine tartrate 2 mg/mL (Simbrinza, Alcon) combines two agents already approved for the treatment of elevated IOP. It is indicated for the reduction of elevated IOP in patients whose monotherapy did not provide sufficient outcomes.

Full Story →